RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company, has announced the issuance of inducement stock options to two newly hired employees. The Compensation Committee of Marinus’ Board of Directors approved these awards as part of the company’s efforts to attract top talent.
The granted non-qualified stock options allow for the purchase of a total of 47,400 shares of Marinus common stock. These options have been set at an exercise price of $8.68 per share, matching the closing price of the company’s stock on April 4, 2024—the date the options were awarded.
The vesting schedule for these options is structured to incentivize long-term employment with the company. One-quarter of the options will become exercisable on the one-year anniversary of the employee’s start date. The remainder will vest in equal monthly installments over the following three years, contingent upon the employee’s continued service with Marinus.
This strategic move, sanctioned under the Nasdaq Listing Rule 5635(c)(4), highlights Marinus Pharmaceuticals’ commitment to leveraging competitive compensation packages to secure and retain industry-leading professionals. Such inducements are pivotal for companies in the highly competitive biopharmaceutical sector, where attracting skilled employees can significantly impact research and development efforts and, ultimately, company success.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.